LU91271I2 - Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) - Google Patents
Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)Info
- Publication number
- LU91271I2 LU91271I2 LU91271C LU91271C LU91271I2 LU 91271 I2 LU91271 I2 LU 91271I2 LU 91271 C LU91271 C LU 91271C LU 91271 C LU91271 C LU 91271C LU 91271 I2 LU91271 I2 LU 91271I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- tysabri
- natalizumab
- pharmaceutically acceptable
- acceptable derivatives
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18626994A | 1994-01-25 | 1994-01-25 | |
PCT/US1995/001219 WO1995019790A1 (fr) | 1994-01-25 | 1995-01-25 | Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91271I2 true LU91271I2 (fr) | 2006-10-02 |
Family
ID=22684288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91271C LU91271I2 (fr) | 1994-01-25 | 2006-08-02 | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1759709B1 (fr) |
JP (5) | JP4115517B2 (fr) |
KR (1) | KR100367948B1 (fr) |
CN (1) | CN1211123C (fr) |
AT (1) | ATE333895T1 (fr) |
AU (1) | AU703152B2 (fr) |
CA (1) | CA2182013C (fr) |
DE (2) | DE69535133T2 (fr) |
DK (2) | DK0804237T3 (fr) |
ES (2) | ES2424292T3 (fr) |
FI (1) | FI117509B (fr) |
FR (1) | FR06C0024I2 (fr) |
HU (1) | HU220799B1 (fr) |
LU (1) | LU91271I2 (fr) |
MX (1) | MX9602971A (fr) |
NL (1) | NL300238I2 (fr) |
NO (3) | NO319867B1 (fr) |
NZ (1) | NZ279730A (fr) |
PL (1) | PL181827B1 (fr) |
PT (1) | PT804237E (fr) |
WO (1) | WO1995019790A1 (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
DK0682529T4 (da) * | 1993-02-09 | 2006-05-15 | Biogen Idec Inc | Antistof til behandling af insulinkrævende diabetes |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
WO1998051345A2 (fr) * | 1997-05-09 | 1998-11-19 | The John P. Robarts Research Institute | Methode permettant de chasser les leucocytes infiltres dans un tissu |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
KR100628818B1 (ko) * | 1998-09-14 | 2006-09-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 인테그린 길항제를 사용하여 다발성 골수종 및 골수종에의한 골흡수를 치료하는 방법 |
US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
RS50086B (sr) * | 1999-04-22 | 2009-01-22 | Biogen Idec Ma Inc., | Upotreba antagonista subjedinica alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze |
DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
ES2529706T3 (es) | 1999-06-01 | 2015-02-24 | Biogen Idec Ma Inc. | Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios |
CA2394431C (fr) * | 1999-12-16 | 2015-06-30 | Jane Relton | Methodes de traitement de lesion ischemique ou hemorragique du systeme nerveux central au moyen d'antagonistes anti-integrine alpha4 |
DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
SK288124B6 (sk) | 2001-04-13 | 2013-09-03 | Biogen Idec Ma Inc. | Anti-VLA-1 antibody, composition comprising such antibodies, isolated nucleic acids sequence, use of composition, in vitro method of determining level of VLA-1 in tissue, cell of cell line hAQC2, haAQC2, hsAQC2 or hybridoma mAQC2 and method for identifying inhibitor of I domain of integrin |
DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
RU2359697C2 (ru) | 2002-02-25 | 2009-06-27 | Элан Фармасьютикалз, Инк. | Введение средств для лечения воспаления |
US7371383B2 (en) * | 2002-04-12 | 2008-05-13 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
TWI323265B (en) * | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
WO2004055056A1 (fr) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Forme humanisee de l'anticorps de souris 14.18 (h14.18) se liant au gd2 et fusion de celle-ci avec il-2 |
CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
CN1917881B (zh) | 2003-12-22 | 2014-11-26 | 味之素株式会社 | 新型苯基丙氨酸衍生物 |
CN101102792A (zh) * | 2004-11-19 | 2008-01-09 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
WO2007061679A1 (fr) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L’INTEGRINE α4β7 |
AU2007267579B2 (en) | 2006-05-25 | 2013-05-30 | Biogen Ma Inc. | Methods of treating stroke |
WO2008103378A2 (fr) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Méthodes de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine |
SI2170390T1 (sl) * | 2007-06-14 | 2019-02-28 | Biogen Ma Inc. | Oblike protitelesa natalizumab |
EP2221325B1 (fr) | 2007-12-13 | 2014-04-16 | Tokuyama Corporation | Composition photochrome durcissable |
BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
WO2010107752A2 (fr) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7 |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
EP3466977B1 (fr) | 2010-04-16 | 2022-01-05 | Biogen MA Inc. | Anticorps anti-vla-4 |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
CN107998388B (zh) | 2011-05-02 | 2023-07-14 | 千禧制药公司 | 抗α4β7抗体的制剂 |
ES2732243T3 (es) | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
US20190225694A1 (en) | 2016-06-28 | 2019-07-25 | Zaklady Farmaceutyczne Polpharma Sa | Recombinant production of monoclonal antibodies |
WO2018091729A2 (fr) | 2016-11-21 | 2018-05-24 | Zaklady Farmaceutyczne Polpharma Sa | Formulations pharmaceutiques aqueuses |
EP3583126A1 (fr) * | 2017-02-17 | 2019-12-25 | Sanofi | Molécules de liaison multispécifiques ayant une spécificité vis-à-vis du dystroglycane et de la laminine-2 |
EP3635093A1 (fr) | 2017-06-08 | 2020-04-15 | Polpharma Biologics S.A. | Méthodes améliorées de culture cellulaire |
EP4284947A1 (fr) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procedes d'évaluation du risque de développement d'une leuco-entéphalopathie multifocale progressive chez les patients traités par des antagonistes de la vla-4 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
IL113261A (en) * | 1989-09-01 | 1996-10-16 | Hutchinson Fred Cancer Res | Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing |
ATE151642T1 (de) * | 1992-02-12 | 1997-05-15 | Biogen Inc | Behandlung für entzündungserkrankung des darmes |
NZ261259A (en) * | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
AUPP647298A0 (en) | 1998-10-13 | 1998-11-05 | Keystone Retaining Wall Systems, Inc. | Retaining wall block |
-
1995
- 1995-01-25 ES ES06013916T patent/ES2424292T3/es not_active Expired - Lifetime
- 1995-01-25 HU HU9602019A patent/HU220799B1/hu active Protection Beyond IP Right Term
- 1995-01-25 DK DK95908741T patent/DK0804237T3/da active
- 1995-01-25 AT AT95908741T patent/ATE333895T1/de active
- 1995-01-25 WO PCT/US1995/001219 patent/WO1995019790A1/fr active IP Right Grant
- 1995-01-25 AU AU16960/95A patent/AU703152B2/en not_active Expired
- 1995-01-25 JP JP51977095A patent/JP4115517B2/ja not_active Expired - Lifetime
- 1995-01-25 PL PL95315634A patent/PL181827B1/pl unknown
- 1995-01-25 NZ NZ279730A patent/NZ279730A/en not_active IP Right Cessation
- 1995-01-25 EP EP06013916A patent/EP1759709B1/fr not_active Expired - Lifetime
- 1995-01-25 EP EP95908741A patent/EP0804237B8/fr not_active Expired - Lifetime
- 1995-01-25 CN CNB951913549A patent/CN1211123C/zh not_active Expired - Lifetime
- 1995-01-25 PT PT95908741T patent/PT804237E/pt unknown
- 1995-01-25 DK DK06013916.9T patent/DK1759709T3/da active
- 1995-01-25 DE DE69535133T patent/DE69535133T2/de not_active Expired - Lifetime
- 1995-01-25 KR KR1019960703987A patent/KR100367948B1/ko not_active IP Right Cessation
- 1995-01-25 CA CA002182013A patent/CA2182013C/fr not_active Expired - Lifetime
- 1995-01-25 ES ES95908741T patent/ES2270425T3/es not_active Expired - Lifetime
- 1995-01-25 DE DE1995635133 patent/DE122006000043I1/de active Pending
-
1996
- 1996-07-24 MX MX9602971A patent/MX9602971A/es unknown
- 1996-07-24 NO NO19963097A patent/NO319867B1/no not_active IP Right Cessation
- 1996-07-24 FI FI962958A patent/FI117509B/fi active Protection Beyond IP Right Term
-
2005
- 2005-08-05 JP JP2005228930A patent/JP2006045237A/ja not_active Withdrawn
-
2006
- 2006-07-27 FR FR06C0024C patent/FR06C0024I2/fr active Active
- 2006-08-02 NL NL300238C patent/NL300238I2/nl unknown
- 2006-08-02 LU LU91271C patent/LU91271I2/fr unknown
- 2006-08-07 NO NO2006008C patent/NO2006008I2/no unknown
-
2009
- 2009-05-18 JP JP2009120421A patent/JP2009235078A/ja not_active Withdrawn
-
2013
- 2013-02-18 JP JP2013028635A patent/JP5487382B2/ja not_active Expired - Lifetime
- 2013-03-18 JP JP2013054628A patent/JP2013165718A/ja not_active Withdrawn
-
2017
- 2017-08-01 NO NO2017040C patent/NO2017040I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91271I2 (fr) | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) | |
LU92912I2 (fr) | Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala) | |
LU91928I2 (fr) | Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®) | |
ATE148130T1 (de) | Typ-iv-dipeptidyl-aminopeptidase-inhibitoren | |
ES2191292T3 (es) | Compuestos antivirales poliaromaticos. | |
MY154009A (en) | Anti-alpha v beta 6 antibodies | |
PT723538E (pt) | Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas | |
BR9807674A (pt) | Inibidores bicìclicos da proteìna farnesil transferase | |
BG101110A (en) | Substituted pyrimidine compounds and their application | |
UA48940C2 (uk) | Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень | |
AP9200410A0 (en) | Retroviral protease inhibitors. | |
DK0989973T3 (da) | Chalconer med antiproliferativ aktivitet | |
ATE199321T1 (de) | Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen. | |
ATE212548T1 (de) | Behandlung und prophylaxe von pankreatitis | |
NO990450D0 (no) | Behandling av sinnslidelser | |
DK1152760T3 (da) | Anvendelse af 4-aminopyridin til behandling af perifere neuropatier | |
ID21920A (id) | 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns | |
FR2721314B1 (fr) | Dérivés de pyrrolidine, leur préparation et les médicaments les contenant. | |
MX9704733A (es) | Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados. | |
MX9704739A (es) | Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados. |